Drug intelligence / Profile preview

AR072

Development stage: Preclinical
Lead developer: Y Biologics

Overview

AR072 is an oncology therapeutic candidate currently in the discovery phase of development by Y Biologics. Intended for the treatment of solid tumors, the specific biological target and therapeutic modality (such as a monoclonal antibody, bispecific antibody, or antibody-drug conjugate) have not yet been publicly disclosed by the developer. The program is part of Y Biologics' early-stage pipeline, which leverages proprietary antibody discovery and engineering platforms to address unmet needs in cancer therapy.

Beyond the preview

Go deeper on AR072.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR072.

Explore the full profile